Price increase for Evonik’s PMMA molding compounds
Effective June 1, 2016, the Evonik segment Performance Materials will increase in the Asia-Pacific region – particularly in China - the prices for selected product types of its PMMA molding compounds, which are marketed under the PLEXIGLAS® and PLEXIMID® trademarks. As far as permissible under existing agreements and according to the product type, the increase will amount between five and seven percent.
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015more than 33,500 employees generated sales of around €13.5billion and an operating profit (adjusted EBITDA) of about €2.47 billion.
Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavour to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.3 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.